Search
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier … It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
AZD-9684
go.drugbank.com/drugs/DB05712ExperimentalAZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.
Vintafolide
go.drugbank.com/drugs/DB05168InvestigationalVintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Vanillyl butyl ether
go.drugbank.com/drugs/DB11299ApprovedIt is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent. … Vanillyl butyl ether is an ether of monohydroxybenzoic acid. It is added to food products as a flavoring agent.
Tripelennamine
go.drugbank.com/drugs/DB00792ApprovedVet approvedA histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. … Tripelennamine is administered by various routes, including topically.
JB991
go.drugbank.com/drugs/DB05081ExperimentalIn addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin. … JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis.
AVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis. … AVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery.
D-JNKI-1
go.drugbank.com/drugs/DB05660InvestigationalA synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the
IR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.